- Date 28 May 2014
- Documents : 4
- History
- (Restricted access link)
Listen
Reason for request
Reassessment of the Actual Benefit of all medicines indicated in hormone replacement therapy for the menopause at the request of the Committee, pursuant to Article R-163-21 of the French Social Security Code
-
Clinical Benefit
| Substantial |
The actual benefit of the proprietary medicinal products UTROGESTAN 100 mg et 200 mg remains substantial in the indication “Replacement therapy for the menopause (in addition to oestrogen treatment). The vaginal route represents an alternative to the oral route in the event of side effects due to progesterone (somnolence after absorption by the oral route)” in non-hysterectomised postmenopausal women and within the limits defined for the use of the oestrogen treatment with which it is combined when the proprietary medicinal products are used in accordance with the recommendations of the Committee. |
Therapeutic use
- |
